🎥 Megan Kruse, MD, of @clevelandclinic.bsky.social, discusses the potential utility of FES-PET/CT in lobular breast cancer for Global Lobular Breast Cancer Awareness Day. #BreastCancerAwarenessMonth #bcsm #oncology

Read on for more lobular disease insights ➡️: www.onclive.com/view/refined...

In this episode of #OncologyUnplugged, Chandler Park, MD, and Jame Abraham, MD, discuss breast cancer management & the role of AI. @clevelandclinic.bsky.social #bcsm #oncology

Watch on our site or listen on your favorite podcast platforms!

www.onclive.com/view/biology...

Revisit the 2025 American Cancer Society report providing statistics on lobular breast cancer in the United States: https://bit.ly/4j6HFAI

The article is also featured in Wiley's #BreastCancerAwareness collection: https://bit.ly/3VNLroL

@americancancersoc.bsky.social
#BCAM #BCSM 🩷

Now out in #JCO!
NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. Co-authored by @Docace911

Read the article. https://bit.ly/3VGspka
#BreastCancer #bcsm

🌟 Matthew P. Goetz, MD, of @mayocliniccancer.bsky.social, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer. #BreastCancerAwarenessMonth #bcsm #oncology

Read more ➡️: www.onclive.com/view/patient...

Q4: What are the next steps for #AYACancer innovation? #AYACSM

#GYNCSM #ONCOLOGY #CANCERRESEARCH #TYACANCER #BTSM #BCSM #LCSM

Q3: Does social media have a role in helping organizations and HCPs be more innovative? How? #AYACSM

#OncSky #HCSMCA #HCSM #LCSM #AMSM #BTSM #BCSM #GYNCSM

🌟 Matthew P. Goetz, MD, of @mayocliniccancer.bsky.social, explores first-line treatment selection & emerging targeted therapies for metastatic breast cancer in honor of Metastatic Breast Cancer Awareness Day. #BreastCancerAwarenessMonth #bcsm #oncology

Read more ➡️: www.onclive.com/view/cdk4-6-...

👀 As #ESMO2026 approaches, we’re preparing to see several potentially practice-informing breast cancer presentations. #bcsm #oncology

Readers weigh in on some of the most talked-about breast cancer abstracts they’re looking forward to seeing ➡️: www.onclive.com/view/poll-re...

New in JCO Oncology Advances: Genomic profiling of 23,760 cases found TP53 alterations in 53%, including the targetable Y220C mutation in 1.1%, and distinct co-alteration patterns—insights for future p53-directed therapies.

Read more: https://bit.ly/4yK2wie
#BreastCancer #bcsm

Last week’s #OncFive:
✅ Atezolizumab approved for CRC #crcsm #oncology
🎗️ Tucatinib approved for breast cancer #bcsm
🩸 IberDd hits PFS in myeloma #mmsm #hematology
🔵 Fast track for VIR-5500 in mCRPC #pcsm
🩸 Epcoritamab+R-CHOP hits PFS in DLBCL #lymsm

www.onclive.com/view/the-onc...

➡️With the development of retzatapopt, combination therapies should be explored for those with MBC & TP53 Y220C alterations
#bcsm

📰 The Guardant360 CDx has received EU approval as a companion diagnostic to identify patients with ER+, HER2– locally advanced or metastatic breast cancer who may benefit from camizestrant. #bcsm #oncology

Full story ➡️: www.onclive.com/view/guardan...

"Practical, balanced, and written in a clear and non-technical style, helping readers navigate treatment decisions and make informed choices.” Jennifer M. Jones, PhD, University Health Network
Learn more about this title: https://bit.ly/4fg7xGD
The National Breast Cancer Coalition #BCSM

Great to be back in Chicago for the 2026 Fall Group Meeting @swog.org working alongside amazing patient advocates! #SWOGonco #oncoalert #bcam #breastcancer #breastcanceractionmonth #clinicaltrials #research #bcsm #cancer #healthequityforall #advocacy

#bcsm #bcam #breastcanceractionmonth #densebreasts #clinicaltrials #healthequityforall #research @swog.org @acscan.bsky.social @oncoalert.bsky.social

Following its May 2026 FDA approval, Dato-DXd has been approved in China for first-line metastatic TNBC ineligible for PD-1/PD-L1 inhibitor therapy #bcsm #oncology

www.onclive.com/view/china-s...

📰 China’s NMPA approved adjuvant T-DXd for HER2+ early breast cancer and residual invasive disease following neoadjuvant therapy with a taxane and trastuzumab. #bcsm #oncology

Full story ➡️: www.onclive.com/view/china-s...

September breast cancer news brought data, approvals, and plenty of expert perspectives. @danafarber.bsky.social @harvardmed.bsky.social @clevelandclinic.bsky.social #BreastCancerBriefing #oncology

Sign up to read a recap of the #bcsm news & insights we reported ➡️: www.onclive.com/view/breast-...

Did you miss any of September's pivotal @fda.gov oncology approvals? Catch up here with the data and significance of each decision #bcsm #lcsm #oncology

Read more: www.onclive.com/view/septemb...